These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 38686045)

  • 21. Peptide-Hitchhiking for the Development of Nanosystems in Glioblastoma.
    Branco F; Cunha J; Mendes M; Vitorino C; Sousa JJ
    ACS Nano; 2024 Jul; 18(26):16359-16394. PubMed ID: 38861272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook.
    Sabir F; Ismail R; Csoka I
    Drug Discov Today; 2020 Jan; 25(1):185-194. PubMed ID: 31629966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surface Engineered Dendrimers: A Potential Nanocarrier for the Effective Management of Glioblastoma Multiforme.
    Sahoo RK; Gupta T; Batheja S; Goyal AK; Gupta U
    Curr Drug Metab; 2022; 23(9):708-722. PubMed ID: 35713127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model.
    Lakkadwala S; Singh J
    Colloids Surf B Biointerfaces; 2019 Jan; 173():27-35. PubMed ID: 30261346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells.
    Hayward SL; Wilson CL; Kidambi S
    Oncotarget; 2016 Jun; 7(23):34158-71. PubMed ID: 27120809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics.
    Tang W; Fan W; Lau J; Deng L; Shen Z; Chen X
    Chem Soc Rev; 2019 Jun; 48(11):2967-3014. PubMed ID: 31089607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functionalized liposomes: an enticing nanocarrier for management of glioma.
    Peddinti V; Rout B; Agnihotri TG; Gomte SS; Jain A
    J Liposome Res; 2024 Jun; 34(2):349-367. PubMed ID: 37855432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma.
    Hsu TI; Chen YP; Zhang RL; Chen ZA; Wu CH; Chang WC; Mou CY; Chan HW; Wu SH
    ACS Appl Mater Interfaces; 2024 May; 16(17):21722-21735. PubMed ID: 38629735
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Gallego L; Ceña V
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticles: Novel vehicles in treatment of Glioblastoma.
    Pourgholi F; Hajivalili M; Farhad JN; Kafil HS; Yousefi M
    Biomed Pharmacother; 2016 Feb; 77():98-107. PubMed ID: 26796272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming brain barriers through surface-functionalized liposomes for glioblastoma therapy; current status, challenges and future perspective.
    Dong C; Yu X; Jin K; Qian J
    Nanomedicine (Lond); 2023 Dec; 18(30):2161-2184. PubMed ID: 38180008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
    Kim SS; Harford JB; Pirollo KF; Chang EH
    Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Penetrating the Blood-Brain Barrier by Self-Assembled 3D DNA Nanocages as Drug Delivery Vehicles for Brain Cancer Therapy.
    Tam DY; Ho JW; Chan MS; Lau CH; Chang TJH; Leung HM; Liu LS; Wang F; Chan LLH; Tin C; Lo PK
    ACS Appl Mater Interfaces; 2020 Jul; 12(26):28928-28940. PubMed ID: 32432847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements.
    Van't Root M; Lowik C; Mezzanotte L
    Curr Pharm Des; 2017; 23(13):1953-1962. PubMed ID: 28025944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy.
    Aparicio-Blanco J; Sanz-Arriazu L; Lorenzoni R; Blanco-Prieto MJ
    Int J Pharm; 2020 May; 581():119283. PubMed ID: 32240807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
    Oberoi RK; Parrish KE; Sio TT; Mittapalli RK; Elmquist WF; Sarkaria JN
    Neuro Oncol; 2016 Jan; 18(1):27-36. PubMed ID: 26359209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma.
    Saha S; Yakati V; Shankar G; Jaggarapu MMCS; Moku G; Madhusudana K; Banerjee R; Ramkrishna S; Srinivas R; Chaudhuri A
    J Mater Chem B; 2020 May; 8(19):4318-4330. PubMed ID: 32330214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment.
    Ganipineni LP; Danhier F; Préat V
    J Control Release; 2018 Jul; 281():42-57. PubMed ID: 29753958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.